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Abstract Serotonin is implicated in many aspects of behavioral regulation. Theoretical attempts
to unify the multiple roles assigned to serotonin proposed that it regulates the impact of costs,
such as delay or punishment, on action selection. Here, we show that serotonin also regulates other
types of action costs such as effort. We compared behavioral performance in 58 healthy humans
treated during 8 weeks with either placebo or the selective serotonin reuptake inhibitor
escitalopram. The task involved trading handgrip force production against monetary benefits.
Participants in the escitalopram group produced more effort and thereby achieved a higher payoff.
Crucially, our computational analysis showed that this effect was underpinned by a specific
reduction of effort cost, and not by any change in the weight of monetary incentives. This specific
computational effect sheds new light on the physiological role of serotonin in behavioral regulation
and on the clinical effect of drugs for depression.
Clinical trial Registration: ISRCTN75872983
DOI: 10.7554/eLife.17282.001
Introduction
Selective serotonin reuptake inhibitors (SSRI) are the most prescribed medications for major depres-
sive episodes (Bauer et al., 2008). The effects of SSRI on improving mood and reducing anxiety
have been well documented (Trivedi et al., 2006; Stahl, 2008; Cipriani et al., 2009) and many
experimental studies showed that serotonin modulates emotional processing even in healthy volun-
teers (Harmer et al., 2009; Serretti et al., 2010). Loss of interest or pleasure in daily activities is
also a key symptom of depression (American Psychiatric Association, 2013). However, the impact
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of SSRI on the motivation deficit (apathy) remains rather controversial (Papakostas et al., 2006;
Weber et al., 2009).
Indeed, several studies reported that SSRI treatments do not reduce apathy as much as other
symptoms (Fava et al., 2014) or can even induce apathy in patients (Barnhart et al., 2004;
Sansone and Sansone, 2010; Padala et al., 2012). However, other studies also reported that SSRI
treatments increase motivation or at least the sensitivity to reward (Tang et al., 2009; Stoy et al.,
2012; Yuen et al., 2014). The related animal literature is also contradictory: some studies on cost/
benefit trade-off showed reduced effort expenditure with SSRIs (Yohn et al., 2016) or no effect with
serotonin blockers (Denk et al., 2005), while other studies reported increased motor activity
induced by SSRI (Weber et al., 2009) or optogenetic stimulation of the dorsal raphe nucleus
(Warden et al., 2012).
One issue with clinical studies is that SSRI effects may be confounded by an interaction with the
pathological state: an SSRI treatment was reported to decrease apathy in late-life depression
(Yuen et al., 2014) and to increase it in Parkinson’s disease (Zahodne et al., 2012). Another issue is
that apathy may not be a simple construct. It is typically captured as a loss of behavioral activation
(Cle´ry-Melin et al., 2011; Treadway et al., 2012), which could arise from different causes at the
cognitive level: for instance a diminished sensitivity to reward attractiveness, or alternatively an exac-
erbated sensitivity to action cost. The ambition of the present study therefore was two-fold: we
aimed (1) to clarify the effects of an SSRI on the motivation of effortful behavior in healthy volun-
teers, unconfounded by psychopathology, and (2) to reconcile these effects with a more general role
of serotonin in the sensitivity to action costs vs. benefits.
Although experimental findings seem diverse at first sight, they might suggest a general role for
serotonin in the behavioral adaptation to action costs. Previous studies suggested that serotonin is
implicated in the motor aspects of action production and also the valuation processes that motivate
the action. Notably, serotonin was found to condition impulse control and the capacity for behav-
ioral inhibition (Cools et al., 2005; Crockett et al., 2009; Warden et al., 2012; Guitart-
Masip et al., 2014) and to promote patience for delayed rewards (Schweighofer et al., 2008;
eLife digest Neuromodulators are chemicals released in the brain that affect the activity of
brain cells. Serotonin is a neuromodulator with the most complicated role: it is released in most
brain regions and affects behavior in diverse ways. Serotonin is implicated in the regulation of
mood, anxiety, impulsivity and learning. Moreover, most medications for depression target
serotonin. A lack of motivation is an important symptom of depression, but exactly how serotonin
affects motivation still remains unclear.
Meyniel et al. studied how increasing the amount of serotonin in the brain affects motivation in
healthy people. The volunteers in the experiments squeezed a handgrip: the longer they squeezed,
the more money they got as a reward. Before the experiment, some of the volunteers received an
antidepressant drug that increases the amount of serotonin surrounding their brain cells, while
others received a placebo.
The experiments revealed that, compared to the people who had the placebo, those who
received the drug put in more effort to get a reward. More serotonin could increase motivation by
reducing the perceived cost of putting in more effort, or by making people value the reward more.
A mathematical model of the results showed that the increased motivation in the antidepressant
group was more consistent with serotonin reducing the cost of putting in an effort, rather than
increasing how much the reward was valued.
Combined with previous findings, these results suggest that serotonin affects the processing of
cost associated with tasks – be that the amount of effort required, delays in getting a reward, or a
punishment. Further experiments are now required to understand if the same mechanism operates
in people with depression, and if so, whether it can be altered to promote recovery. It will also be
important to better understand the interaction between serotonin and other neuromodulators such
as dopamine.
DOI: 10.7554/eLife.17282.002
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Miyazaki et al., 2014; Worbe et al., 2014). Serotonin also impacts the determinants of actions, for
instance, how positive and negative outcomes guide learning in humans (Chamberlain et al., 2006;
Crockett et al., 2009; Faulkner and Deakin, 2014), monkeys (Clarke et al., 2004) and rodents
(Bari et al., 2010). Several attempts have been made previously to capture serotonin function in a
coherent computational theory. Key ideas are that serotonin (1) regulates the impact of action costs
such as punishments (Daw et al., 2002; Niv et al., 2007) or delay (Niv et al., 2007; Cools et al.,
2011; Miyazaki et al., 2014) and (2) adjusts the propensity to activate versus inhibit the action
(Boureau and Dayan, 2011; Cools et al., 2011).
Borrowing from these models, we retain the general working hypothesis that serotonin regulates
behavioral activation by modulating the weight of action costs rather than benefits.
We further suggest that the notion of action cost could be more general than initially envisaged.
Indeed, in the literature quoted above, actions are mostly implemented as binary responses (e.g.,
approach vs. avoidance) and their costs or benefits are manipulated through the valence of their out-
come (e.g., monetary gain or loss). Such tasks therefore over-simplify the real-life situation, where
actions may often require more or less effort, depending on their intensity and duration.
Figure 1. Task design and behavioral performance. (A) The screenshots depict a trial as it was presented to subjects.Subjects were free to allocate their
effort as they wished over the 30s corresponding to the trial duration. They were instructed that their monetary payoff would be proportional to both
the monetary incentive and the effort duration, i.e. the time spent squeezing a handgrip harder than a target force level, which varied with task
difficulty. Subjects were provided with on-line feedback on the payoff accumulated in the trial (score on the top) and on the instantaneous pressure
exerted on the grip (fluid level in the thermometer). The force time series of an example trial is shown below the screenshots, revealing 3 effort periods,
with rewarded effort (force above target) plotted in black (not gray). Two factors were manipulated across trials: (i) the incentive level, shown as a coin
image (1, 2 or 5p) and (ii) the difficulty level, corresponding to the same white bar in the thermometer reached with different target force levels (70%,
80% or 90% of the maximal force). The last screen summarized the payoff cumulated over preceding trials. (B) Using a double-blind procedure, healthy
subjects were assigned to one of the two treatment groups, corresponding to a daily intake of either placebo or escitalopram (10 mg during the initial
phase, 20 mg during the intermediate and late phase) during 9 weeks. Each subject completed the effort allocation task three times at distinct
treatment phases (initial, intermediate and late). Numbers of subjects and visits correspond to data sets included in the analysis after compliance and
quality checks. (C) The three left-most graphs show task performance (as reflected in monetary payoff) sorted by treatment group (black: placebo; gray:
escitalopram) and time since treatment onset. Statistical significance was assessed with two-sample, two-sided t-tests. On the right-most plot, payoff
was averaged over visits at the subject level. Statistical significance was assessed with ANOVAs including treatments as between-subject factors and
test phase (initial, intermediate or late) as a within-subject factor. *p<0.05; **p<0.005. Error bars indicate Student’s 95% confidence intervals.
DOI: 10.7554/eLife.17282.003
The following source data is available for figure 1:
Source data 1. The MATLAB data file contains the payoff earned by each participant at each visit, in the placebo and escitalopram groups.
DOI: 10.7554/eLife.17282.004
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Here, we tested the specific hypothesis that serotonin regulates the weight of effort cost in action
production, as opposed to the weight of expected benefit. To assess the impact of changing cere-
bral serotonin levels and how it unfolds over time, we compared different groups of healthy subjects
treated under double blind conditions with escitalopram (an SSRI) or placebo during eight weeks.
Participants performed a previously published task (Meyniel et al., 2013), during which they allo-
cated physical effort over time in order to maximize a monetary payoff that increased with effort
duration (see Figure 1A). The task thus involves trading a physical effort cost against distinct levels
of monetary incentives. Although changes in cost and benefit were independently manipulated in
the task, they may result in intricate effects at the behavioral level. To disentangle between potential
effects of serotonin on cost or benefit estimates, or both, we used a formal model of how decisions
are generated by a hidden level of computations in our task, as previously described (Meyniel et al.,
2013, 2014). Based on this computational analysis of the behavior, we could pinpoint the specific
effect of serotonin on cost-related parameters, and track the predicted effects of such a computa-
tional change onto the experimental measures.
Results
Escitalopram improves performance in the effort allocation task
58 subjects were included in the analysis, see Table 1. We took the cumulated payoff as the primary
measure of performance in the task and compared it between groups and visits (see Figure 1C). We
found a significant effect of treatment group: performance was significantly improved in the escitalo-
pram group (F1, 58.4=9.37, p=0.003) as compared to the placebo group. This difference was stable
over time: there was no significant interaction between groups and visits (F2, 91=0.22, p=0.8). The
average payoff per visit was £35.9±1.21 s.e.m. and £30.1±1.44 s.e.m. in the escitalopram and pla-
cebo groups respectively.
Escitalopram has a specific computational effect on effort cost
The better performance observed in the escitalopram group could be underpinned by different
mechanisms: alleviation of effort costs or inflation of incentive values, or both. To disentangle
between the two mechanisms, we relied on a computational model of effort allocation that was pre-
viously proposed (Meyniel et al., 2013; Meyniel et al., 2014). This model assumes that a single
computational variable, termed cost evidence, accounts for the decision to stop and resume effort
exertion. Cost evidence waxes during effort (with slope Se) until reaching an upper bound where
effort is stopped, and it wanes during rest (with slope Sr) until reaching a lower bound where effort
is resumed. The distance between bounds is the cost-evidence amplitude (denoted A). Effort and
rest durations are determined by the ratios of amplitude and slopes (see Figure 2A) so that perfor-
mance depends on the value of latent parameters (A, Se, Sr) and its potential modulation by task
factors (monetary incentive and effort difficulty). We used a Bayesian Model Selection procedure
previously validated (Meyniel et al., 2013, 2014) to pinpoint the effect of the task factors onto
these latent parameters (see Materials and methods).
Replicating our previous studies, the best model showed that incentives impacted the amplitude
(A) and dissipation slope (Sr), whereas effort difficulty impacted the accumulation slope (Se), as illus-
trated in Figure 2A, right. To capture all the effects, the cost-evidence accumulation model there-
fore necessitates five free parameters: the mean slope of cost-evidence accumulation (Sem) and its
steepening for higher difficulty levels (Sed); the mean slope of cost-evidence dissipation during rest
(Srm) and its steepening for higher incentives (Sri); and the expansion of the cost-evidence amplitude
as higher incentives push the bounds back (Ai). The fact that the same best model was found inde-
pendently in each treatment group with high confidence levels (exceedance probabilities xp>98% in
each group) indicates that all subjects can be characterized within this common computational
framework. We computed for each subject the best-fitting values of the model parameters (Ai, Sem,
Sed, Srm, Sri). Since the interaction between treatments (placebo vs. escitalopram) and treatment
phase was not significant for any parameter (all F2, 91<2.03, p>0.14), we provide fitted values pooled
over treatment phases in Figure 2B.
Only one model parameter was significantly different between the placebo and escitalopram
groups: the cost-evidence accumulation slope (Sem, F1, 58.0=9.88, p=0.003). This parameter captures
Meyniel et al. eLife 2016;5:e17282. DOI: 10.7554/eLife.17282 4 of 18
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Figure 2. Computational results. (A) The cost-evidence accumulation model assumes that effort and rest durations are respectively determined by the
accumulation (mean slope Sem) and dissipation (mean slope Srm) of cost evidence between bounds (mean amplitude Am). Possible modulations of
these parameters by incentive and difficulty levels were implemented in 20 distinct models. In the best model identified (#20) by Bayesian selection,
increasing effort difficulty shortens effort duration by steepening the accumulation slope (a parametric effect controlled by parameter Sed and
illustrated with colors from yellow to red). Increasing the incentive level has two effects: first, it shortens rest duration by speeding up the dissipation
(parametric effect of Sri, illustrated by colors from dark to light blue); second, it lengthens effort duration by pushing back the bounds (parametric effect
of Ai, illustrated by green scaling). (B) Plots show inter-subject means and Student’s 95% confidence intervals obtained for the fitted values of model
parameters (which were averaged over visits at the subject level). To facilitate visual comparison, scales and offsets were adjusted so that mean and
error bars are visually equal across plots in the placebo group. Statistical significance corresponds to ANOVAs including treatment group (escitalopram
vs. placebo) as a between-subject factor and treatment phase as a within-subject factor (initial, intermediate or late); **p<0.005. (C) Data in the placebo
group served as a baseline to simulate effort and rest durations after imposing a 20% increase in computational parameters. In the table, each row
corresponds to a simulated change in one single parameter. Colors denote the effect sizes recovered by model fitting for each parameter, as percent
of change compared to baseline. Numbers indicate the percentage of ’hit’ (on the diagonal) and ’false alarm’ (off-diagonal) in detecting a significant
change in parameter values with a paired t-test thresholded at p<0.01. (D) The graph illustrates why the effect of escitalopram, characterized at the
computational level as a reduced accumulation slope of cost-evidence during effort (Sem), should translate at the behavioral level into both a longer
effort duration and an increased sensitivity of effort duration to incentive level.
DOI: 10.7554/eLife.17282.005
The following source data is available for figure 2:
Source data 1. The MATLAB data file contains the fitted value of parameters Ai, Sem, Sed, Srm, Sri (see Materials and methods, Equation 2), for each
participant at each visit, in the placebo and escitalopram groups.
DOI: 10.7554/eLife.17282.006
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the average value of effort cost across conditions: there was a 31% decrease in the escitalopram
group compared to the placebo group (on average with ± s.e.m., placebo: 0.16±0.012, escitalopram:
0.11±0.008); the difference was actually significant at each visit (all p<0.015; two-sided t-test).
The difference between escitalopram and placebo never reached significance for the other model
parameters (all p>0.08, see Table 2; on average with ± s.e.m. for placebo vs. escitalopram, Ai:
0.15±0.028 vs. 0.19±0.022, Sed: 0.021±0.004 vs. 0.013±0.002, Srm: 0.37±0.022 vs. 0.42±0.029, Sri:
0.086±0.018 vs. 0.126±0.016). We checked the sensitivity and specificity of our model fitting proce-
dure in detecting a treatment effect through simulations. A 20% change in any given parameter was
reliably detected and the difference recovered by model fitting was significant in a 96% of simula-
tions at least for Ai, Sem, Srm and Sri and in a 77% of simulations for Sed. Importantly, a change in
one single parameter was recovered without propagating to other parameters and the false alarm
rate was below 5% for all parameters (Figure 2C).
To further test the specificity of SSRI effect on cost-evidence accumulation, we performed another
Bayesian model selection that contrasted the two groups of subjects. Parameters of the cost-evi-
dence accumulation model were fitted on the placebo group data to serve as a reference. In the
Table 1. Details on participants N corresponds to the number of subjects per treatment type and phase. A few datasets were not
available due technical problems and late withdrawals. Based on criteria specific to the present task (and not to the clinical trial), some
subjects were excluded from the analysis (’excluded’). We report the age and sex of participants included in the analysis and the exact
time of their test since the treatment onset.
Treatment
type
Treatment
phase
N not
available
N
excluded
N after
exclusion
Sex (Male /
female)
Age (years) ± SD of
included subjects
Time since treatment onset (days) ± SD
for included subjects
Placebo Initial 0 5 27 14/13 23.4 ± 4.35 3.0 ± 0.68
Placebo Intermediate 0 6 26 14/12 23.2 ± 4.33 13.8 ± 1.13
Placebo Late 0 4 28 15/13 23.4 ± 4.27 54.7 ± 4.98
Escitalopram Initial 1 8 23 11/12 24.5 ± 4.71 3.1 ± 0.63
Escitalopram Intermediate 1 6 25 12/13 24.5 ± 4.51 14.0 ± 0.87
Escitalopram Late 2 6 24 10/14 24.6 ± 4.61 55.3 ± 4.69
DOI: 10.7554/eLife.17282.007
Table 2. Treatment effect on computational parameters and behavioral measures.
All numbers are p-values obtained from ANOVAs. p-values lower than 0.05/5=0.01 (computational
parameters) and 0.05/6=0.008 (behavioral measures) appears in bold to show significant effects that
survive correction for multiple comparisons.
Variable Treatment Visit Interaction
Ai 0.388 0.197 0.406
Sem 0.003 0.039 0.260
Sed 0.0797 0.543 0.137
Srm 0.186 0.778 0.612
Sri 0.130 0.196 0.557
Effort duration – mean 0.002 0.199 0.875
Effort duration – sensitivity to incentive 0.023 0.187 0.115
Effort duration – sensitivity to difficulty 0.247 0.813 0.318
Rest duration – mean 0.213 0.482 0.531
Rest duration – sensitivity to incentive 0.162 0.937 0.807
Rest duration – sensitivity to difficulty 0.115 0.423 0.681
DOI: 10.7554/eLife.17282.008
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escitalopram group, they were fixed to these reference values and only one or two modulations
were permitted to capture the treatment effects. Models including a modulation of Sem outper-
formed the others (log Bayes Factor, all D>147.9), see Table 3. A version with modulations of both
Sem and Sed was slightly more likely than a version with only a modulation of Sem (D=3) and much
more likely than any other combination (D>5.9).
Table 3. Model comparison assessing the specificity of treatment effect.
Data in the escitalopram group were fitted with the cost-evidence accumulation model. The parameters
were fixed to the values fitted onto the placebo group, excepted when a modulation was permitted. The
first row contains models that permit the modulation of one single parameter, whereas the remaining
rows correspond to models that permit a combination of two modulations. Each cell gives log Bayes
Factor (i.e. log model evidence) relative to the null model. Higher values denote better models.
Sem Sed Srm Sri Ai
Only one modulation 173.6 19.9  4.2  3.8 3.7
Also includes Sem 176.6 169.6 169.7 170.7
Also includes Sed 15.7 16.1 21.7
Also includes Srm  7.3  1.1
Also includes Sri 1.2
DOI: 10.7554/eLife.17282.009
Figure 3. Behavioral results. (A) Plots show inter-subject means and Student’s 95% confidence intervals obtained
from linear regression.Regression coefficients were averaged over visits at the subject level. To facilitate visual
comparison, scales and offsets were adjusted so that mean and s.e.m. are visually equal across plots in the
placebo group. Statistical significance corresponds to ANOVAs including treatment group (escitalopram vs.
placebo) as a between-subject factor and treatment phase as a within-subject factor (initial, intermediate or late);
*p<0.05, **p<0.005. (B) As predicted by the cost-evidence accumulation model, effort duration and its sensitivity
to incentive level are correlated across subjects (one dot corresponds to one subject; values were averaged across
visits for each subject). The line shows the linear regression fit obtained when pooling the two treatment groups
(r56=0.55, p<10
–5).
DOI: 10.7554/eLife.17282.010
The following source data is available for figure 3:
Source data 1. The MATLAB data file contains a description of the behavior obtained by linear regressions for
each participant at each visit, in the placebo and escitalopram groups.
DOI: 10.7554/eLife.17282.011
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Thus, the specific effect of SSRI on cost-related parameters supports our hypothesis that seroto-
nin is involved in the estimation of action cost, rather than benefits.
Computational effects of escitalopram translate into behavioral effects
Reducing the effort cost (Sem) only should have two effects at the behavioral level (see Figure 2D).
The first is straightforward: the duration of effort epochs should be longer. The second is less trivial:
the sensitivity of effort duration to incentive level should be increased. This is because in our model,
incentive level modulates the amplitude between bounds (as captured by parameter Ai). Thus, the
effect of incentive level on effort duration is proportional to the accumulation slope Sem: if the accu-
mulation is slower, then a given displacement of the upper bound will have a larger effect on effort
duration.
Fulfilling these predictions, we found both a longer effort duration per se (F1, 58.1=10.72,
p=0.002, on average placebo: 7.63s±0.56, escitalopram: 10.2s±0.55, with s.e.m.) and a higher sensi-
tivity of effort duration to incentive level (F1, 58.5=5.46, p=0.023, on average with ± s.e.m., placebo:
1.11±0.22, escitalopram: 1.95±0.26) in the escitalopram group compared to placebo (see
Figure 3A). The difference between the two treatment groups never reached significance for the
other behavioral variables (all p>0.11, on average with ± s.e.m., for placebo vs. escitalopram, effort
sensitivity to difficulty:  0.84±0.13 vs.  1.06±0.14, rest duration: 3.17s±0.19 vs 2.85s±0.19, rest sen-
sitivity to incentives:  0.19±0.04 vs.  0.30±0.05, rest sensitivity to difficulty: 0.077±0.018 vs.
0.025±0.03).
Crucially, because they arise from a common cause, the model also predicts that the two effects
should be correlated: the more Sem is reduced, the more effort duration and its sensitivity to incen-
tive level should be increased. The Pearson correlation over subjects was indeed significantly positive
in both groups (placebo: r27=0.43, p=0.02; escitalopram: r27=0.54, p=0.002, see Figure 3B).
Discussion
Our behavioral results in healthy volunteers show that the SSRI escitalopram improves global perfor-
mance and hence payoff in a task that involves trading effort cost against monetary benefit. Taking
advantage of the independent manipulation of cost and benefit, our computational analysis charac-
terized the effect of escitalopram as a specific diminution of effort cost.
Together with previous findings, our results support the hypothesis that cost may be a general
functional domain for serotonin (Boureau and Dayan, 2011; Dayan, 2012). For instance, interven-
tions targeting serotonergic transmission during probabilistic and reversal learning paradigms in
rodents, monkeys and humans suggested that serotonin impacts sensitivity to negative rather than
positive feedback (Clarke et al., 2004; Chamberlain et al., 2006; Crockett et al., 2009; Bari et al.,
2010; Cohen et al., 2015). The reduction of serotonergic transmission in humans following acute
tryptophan depletion (for a review, see Faulkner and Deakin, 2014) reduced information sampling
in a decision-making task, but crucially, only when sampling had a financial cost (Crockett et al.,
2012). Serotonin may also impact moral costs, such as unfairness in social decision-making
(Crockett et al., 2008). Furthermore, serotonin may control the cost of delay in reward delivery in
rodents, such that a higher firing rate of serotonergic neurons correlates with an increased ability to
wait for bigger rewards (Miyazaki et al., 2014), without affecting the sensitivity to the reward itself
(Fonseca et al., 2015). Conversely, low serotonin levels, e.g. after acute tryptophan depletion, were
suggested to exacerbate sensitivity to the cost of waiting, which could result in impulse control dis-
orders (Crockett et al., 2009; Cools et al., 2011; Dayan, 2012). Thus, it is tempting to build a parsi-
monious computational theory on the idea that serotonin is involved in processing all kinds of action
costs. This is compatible with the notion that different types of costs are processed by distinct neural
circuits, since neuromodulators such as serotonin can affect many brain regions. However, such a
generalization would necessitate assessing the putative role of each mono-amine and their interac-
tions with different types of costs within the same study. Previous attempts in rodents have observed
effects that are inconsistent with the present results: in cost/benefit trade-off tasks, serotonin block-
ers impacted choices only when costs were delays, and not physical efforts (Denk et al., 2005),
whereas dopamine blockers affected both types of costs. Such discrepancies may call for caution
when translating the results of pharmacological studies in rodents into medication effects in humans.
Meyniel et al. eLife 2016;5:e17282. DOI: 10.7554/eLife.17282 8 of 18
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A general role for serotonin in cost processing also seems compatible with the effects on apathy
and impulsivity reported in healthy and pathological conditions (Cools et al., 2005;
Papakostas et al., 2006; Schweighofer et al., 2008; Crockett et al., 2009; Weber et al., 2009;
Warden et al., 2012; Guitart-Masip et al., 2014; Miyazaki et al., 2014; Worbe et al., 2014).
Indeed, according to our interpretation, SSRIs might reduce the perceived cost of performing
actions, which would promote behavioral activation, hence the alleviation of apathy. As SSRIs might
also reduce the perceived cost of delaying action, they would improve response control and reduce
impulsivity (Cools et al., 2005; Cools et al., 2011; Crockett et al., 2009; Dayan, 2012; Bari and
Robbins, 2013; Miyazaki et al., 2014; Fonseca et al., 2015).
However, it is important to note that the SSRI effects obtained here relate to effort cost and not
to time discounting. Although time is central in our task, it departs from delay and waiting para-
digms in several respects. First, the overall task duration was fixed and its pace was independent
from how subjects allocated their effort within trials. Second, the reward was gained instantaneously,
concomitantly to effort production, without delay. Therefore, the SSRI effect on effort duration (how
long subjects sustain an effort) cannot be explained by a change in temporal discounting (how long
subjects wait for a reward).
The direction of the effect obtained in the present study suggests that higher serotonin level alle-
viates the effort cost. This interpretation is based on the assumption that the primary effect of SSRI
is to increase serotonin level in the synaptic cleft (Nutt et al., 1999; Stahl, 2008). However, the net
effect of SSRI might not be so straightforward to interpret at the molecular level for several reasons.
First, a high tonic concentration could have the paradoxical effect of reducing the sensitivity to pha-
sic serotonergic signals (Faulkner and Deakin, 2014). Second, the ubiquitous negative feedback
regulation by auto-receptors can initially revert the response expected from high extracellular levels
of serotonin (Stahl, 2008; Fischer et al., 2014) and also produce non-linear dose-response functions
for cognitive performance (Bari et al., 2010). Third, much evidence suggests that different serotonin
projections to different forebrain systems mediate varying acute and chronic adaptive responses to
aversive events (Hale et al., 2013; Faulkner and Deakin, 2014). The effect of serotonin also
depends on the location in the brain and on the type of receptors, for instance, 5-HT1A and 5-HT2A
receptors respectively inhibit and excite motoneurons (Jacobs and Azmitia, 1992). Thus, the super-
ficial interpretation that serotonin helps overcoming effort costs will need to be refined by address-
ing the complexity of SSRI effects at the molecular level. We nevertheless note that the superficial
interpretation is consistent with demonstrations that serotonin also helps overcoming other costs
such as delay in humans (Schweighofer et al., 2008).
Refinement is also needed at the computational level. Our model does not specify how exactly
serotonin could attenuate the impact of effort cost on action production. An indirect effect through
an increase in muscular capacity can be excluded since there was no difference in maximal force
between the placebo and SSRI groups at any visit. The computational analysis simply suggests that a
slower accumulation of effort cost (lower Sem) under SSRI prolonged effort duration. It does not dis-
tinguish between down-regulation of the cost signal itself, or down-regulation of the weight this cost
has in the decision to produce an effort. The former (perceptual) view would be in line with an anal-
gesic effect of escitalopram, which is consistent with the findings that nociception and/or somato-
sensory perception are both modulated by serotonin at central levels (Jacobs and Azmitia, 1992),
that serotonin is targeted by common drugs modulating pain like acetaminophen (Smith, 2009) and
that serotonin modulates the inhibitory feedback loop that allows muscular fatigue to down-regulate
the motor command (Gandevia, 2001; Cotel et al., 2013). The latter (decisional) view would be
more generalizable to the capacity of overcoming other types of costs.
As the serotonin and dopamine systems strongly interact (Dremencov et al., 2009; Cools et al.,
2011; Schilstro¨m et al., 2011; Fischer et al., 2014), the SSRI effect observed here might also be at
least in part mediated by dopamine. Indeed, the beneficial effect of SSRI shown here is reminiscent
of previous reports about dopaminergic manipulations in mesolimbic structures, which affected the
propensity to choose high reward – high effort over low reward – low effort options in rodents
(Cousins et al., 1996; Salamone et al., 2007). However, if SSRIs antagonize dopamine release
(Dremencov et al., 2009; Cools et al., 2011), escitalopram should have reduced effort production
in our task (but see Schilstro¨m et al., 2011). Moreover, the fact that escitalopram did not modulate
incentive effects on parameters such as the amplitude or dissipation slope argues against a partici-
pation of dopamine. Indeed dopaminergic manipulations in humans have been repeatedly shown to
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affect reward processing, not only in learning contexts (Frank et al., 2004; Pessiglione et al., 2006;
Palminteri et al., 2009) but also in reward/effort trade-off paradigms (Wardle et al., 2011;
Treadway et al., 2012; Le Bouc et al., 2016). It might be that serotonin and dopamine have com-
plementary roles in promoting action production (and alleviating apathy): the former by reducing
effort cost and the latter by enhancing the incentive value of potential rewards.
Previous studies suggest that we should distinguish between acute and chronic effects of SSRIs
(Fischer et al., 2014). We did not find an interaction with time in our results but only a main effect
of treatment group. Both parametric and non-parametric statistics showed that such a group differ-
ence is very unlikely to arise from chance in sampling the population (under the null hypothesis).
General psychological assessment at baseline was also similar in the two groups. However, we
acknowledge that our shortest time since treatment onset (3 days) may already depart from the
acute regime, that ceiling effects in the SSRI group could in principle mask an interaction with time,
and that our study may lack the statistical power to reveal such an effect. This absence of an interac-
tion contrasts with the apparently delayed clinical effect of SSRIs in depressed patients, which usually
take weeks to improve mood (Stahl, 2008). However, at the molecular level, serotonin release is
boosted by SSRIs from treatment onset (Kobayashi et al., 2008) and SSRI effects on emotional
processing also occur with little or no delay in healthy subjects (Harmer et al., 2003). In pathological
conditions, time may be needed to adjust to the new, less negative perception of costs, as well as
the reduced emotional bias, and convert these implicit changes into a conscious subjective improve-
ment that can be reported to the practitioner (Harmer et al., 2009; Cools et al., 2011). This idea
has been formalized in a recent study showing how positive and negative outcomes can shape
mood on the long run (Eldar and Niv, 2015). Further studies in depressed patients are needed to
assess whether an early detection of effort cost attenuation could be used to predict long-term
treatment effects on clinical symptoms.
Finally, our results also indicate that non-trivial behavioral effects can be accounted for by a
change in a single computational parameter (Sem): a specific modulation of cost can result in both
longer efforts and an increased sensitivity of effort duration to potential benefits in our results. Intui-
tively, this effect on reward sensitivity corresponds to the idea that when perceived costs are too
high, a change in reward prospect will have little effect. Thus, our analysis shows that the behavioral
consequences of cost and benefit estimates are intricate but computationally tractable. Our para-
digm and model could provide experimental and conceptual tools to refine the description of moti-
vational disorders. Distinct dysfunctions, such as amplification of effort cost vs. flattening of reward
prospects, might call for different treatments: if drugs modulating serotonin only affect cost esti-
mates, then other drugs (possibly dopaminergic) should aim to impact the valuation of potential
benefits.
Materials and methods
Participants
Healthy volunteers (18–45 years old) were recruited to the study by public advertisement after
approval by the Ethics Committee of Berkshire, UK (protocol CL1-20098-81, on 28th Sept. 2011) and
registration as a clinical trial, ISRCTN75872983. Participants gave their written informed consent
prior to participation. Normal health was checked by clinical and psychiatric examinations including
laboratory tests. Exclusions and withdrawals from the study were adjusted to include 64 participants
(2 treatment groups of 32 participants, 16 men per group), tested at 3 separate visits, resulting in
192 completions of the task. Given that the clinical trial was exploratory and also included tests from
other research groups, the sample size was not selected specifically for our study; however it
appeared reasonable given typical studies in the field. Indeed, published between-subject compari-
sons of placebo and anti-depressant treatments were made on a lower sample size per group (e.g.
N=14 in Harmer et al., 2004, N=20 in Chamberlain et al., 2006 and N=30 in Guitart-Masip et al.,
2014), and a single visit per subject (while we have three). Due to technical problems or late with-
drawals, 4 task completions were not fully acquired and therefore unusable. The remaining data
were checked for quality by F.M. prior to unblinding: 11 were excluded due to mis-calibration of
task difficulty; 9 due to hardware default or signal quality; 15 for non-compliance with task instruc-
tions. Subjects were asked to produce an effort in every trial. As there were eight trials per condition
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in the task, a given visit was excluded for non-compliance when the total number of effort (or rest)
was lower than three in at least one condition. As a result, the number of participants per visit varied
between 23 and 28 in each treatment group, for a total of 153 task completions. Note that a given
participant may produce an interpretable dataset at a given visit and not at another. The total num-
ber of participants with at least one interpretable dataset across the three visits happened to be 29
in each treatment group. The finally included data set is summarized in Table 1.
Sex ratio (14/29 vs. 16/29, Z test for proportion: z= 0.53, p=0.6), ratio of excluded data sets (15/
96 vs. 20/92, z=1.08, p=0.28) and age (mean with ± s.e.m., 23.2 ± 0.8 vs. 24.2 ± 0.8, p=0.38) were
similar in the two groups. We also used psychological tests to assess differences between groups of
subjects at baseline, before treatment. T-test comparison showed no significant difference in Mood
Visual Analog Scales for the items ’happy’ (p=0.75), ’sad’ (p=0.96), ’hostile’ (p=0.48), ’alert’ (p=0.73),
’anxious’ (p=0.51), ’calm’ (p=0.14), nor in the Hospital Anxiety Depression score for anxiety (p=0.68)
and depression (p=0.35). The difference in State-Trait Anxiety Inventory score was at p=0.04 at
baseline but p=0.45 and p=0.83 after 7 and 55 days of treatment respectively. Therefore, psycholog-
ical variables were not significantly different at baseline when correcting for multiple comparisons (at
p=0.05/9) and the one passing the uncorrected threshold p=0.05 was not significantly different dur-
ing the testing phase.
Drug and testing schedule
Two centers participated in the study (Oxford and Manchester, UK). Data were collected between
January 2012 and July 2013. Participants were randomly assigned to one of the two parallel treat-
ment groups following a double-blind procedure: placebo or escitalopram (10 mg during week #1
and #9; 20 mg from week #2 to #8). The randomisation list was constructed in blind, by the Institut
de Recherches Internationales Servier, with stratification by gender and center (Oxford, Manchester).
Treatments were conditioned by Les Laboratoires Servier Industrie so as to be visually indistinguish-
able and shipped in numbered containers to the investigators. The randomisation list was not made
available to the investigators until the final data set had been checked for quality and locked by
transfer to a Contract Research Organization (Biotrial). Participants took a daily oral capsule around
8 P.M. for 9 weeks and performed the Effort Allocation Task three times at distinct latencies
(Figure 1B): initial (2–4 days after treatment onset), intermediate (12–17 days) and late (52–60 days
for all subjects but 3, who were tested between the 33rd and 44th days before withdrawing from
the study). The task was not performed on week #9. The clinical trial included other tests, not pre-
sented here, to assess emotional processing, sexual acceptability and learning abilities. Safety evalu-
ations (adverse events collection, blood pressure/heart rate and laboratory test) were performed
along with the study.
Experimental set-up
The Effort Allocation Task is schematized in Figure 1A and detailed in a previous publication
(Meyniel et al., 2013). The only change was the adoption of the local currency (British pounds). On
each trial, participants had 30 s that could be spent either resting or squeezing a handgrip. They
were instructed that the payoff would be proportional to both the monetary incentive and the time
spent above a force target corresponding to effort difficulty. The task lasted approximately one hour
and was split into 8 blocks. The factor levels (monetary incentives: 1, 2 or 5p and effort difficulty: 70,
80, 90% of the maximal force) were manipulated independently and crossed, resulting in 9 condi-
tions, each corresponding to a trial, presented in a randomized order in each block. Left and right
hands were used alternatively over blocks. Participants were encouraged to maximize their payoff at
each trial, and told that the cumulated payoff would be added to their financial compensation for
participating in the study. Unbeknown to them, this payoff was rounded up to a fixed amount after
the last visit such that all participants eventually received the same total. The task difficulty was
adjusted to the subject’s maximal force, which was measured at each visit before the test. The pro-
cedure for measuring the maximal force (sustained handgrip squeezing) is detailed in
(Meyniel et al., 2013) and follows published guidelines (Gandevia, 2001). The maximal force was
not affected by treatments (F3, 113.7=0.93, p=0.42), visits (F2, 180=1.34, p=0.26) or by the interaction
of these two factors (F6, 180=0.27, p=0.95).
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Behavioral analysis
The cumulated effort duration determined the payoff obtained at each trial. Yet there are many
ways of chunking this cumulated duration depending on the duration of each effort and rest epochs.
Effort and rest epochs were determined based on the force time series (Figure 1A provides an
example) using an off-line algorithm (Meyniel et al., 2014). The offline detection algorithm was
based on both the force signal normalized by the calibration maximal force, and its temporal deriva-
tive. Samples with positive derivative, exceeding one standard deviation of the derivative time
series, and force level higher than 0.5 (half the maximum) were tentatively marked as effort onsets.
Effort offsets were defined similarly for negative derivative values and force levels below 0.5. When
multiple offsets were detected between two onsets, all but the last one were discarded. If multiple
onsets were detected before an offset, the one with minimum force was kept. An offset was marked
at the trial end if the effort was still sustained at that moment. Elapsed time between effort onsets
and offsets determined effort and rest durations. The first rest duration was the elapsed time
between trial onset and the first effort onset.
We performed a model-free analysis of the behavior, for each subject and visit, with multiple lin-
ear regressions done separately for effort and rest durations. The linear models included the factors
of interest (incentive and difficulty) and temporal factors (block number; trial number within a block,
effort or rest epoch number within a trial). Regressors (excepted the constant) were z-scored so that
regression coefficients (beta estimates) correspond to standardized effect sizes. These beta values
were then compared between treatments using ANOVA (see statistical analysis below).
Computational analysis
The cost-evidence accumulation framework
To account for the decision to stop and resume effort exertion in our task, we previously developed
a computational model that was supported by both behavioral and neuroimaging data
(Meyniel et al., 2013; Meyniel et al., 2014). The central assumption of our model is that the alloca-
tion of effort over time is underpinned by the variation of a single computational variable. This deci-
sion variable waxes during effort until reaching an upper bound, which triggers effort cessation, and
wanes during rest until reaching a lower bound, which triggers effort resumption. The model thus
has three latent parameters: the accumulation (Se) and dissipation (Sr) slopes of cost evidence and
the amplitude of these variations (A; the distance between bounds). The ratios of amplitude and
slopes determine the effort and rest durations (see Figure 2A).
The computational analysis, detailed below, aimed at (1) identifying how the model latent param-
eters are modulated by the task factors (incentive and difficulty levels), (2) testing whether these
modulations differ between treatment groups and (3) assessing the specificity and sensitivity of our
fitting procedure in detecting potential differences between treatment groups.
Model fit and selection
In this section, we provide details about model fit and model selection, although we followed the
exact same methods as reported in our previous publication (Meyniel et al., 2013).
In principle, each model latent parameter (accumulation slope Se, dissipation slope Sr and ampli-
tude of variations A) could be modulated by each task factor, which we formalized as linear effects:
Te¼ A
Se
;Tr¼ A
Sr
;
A ¼ AmþAiIþAdD
Se ¼ Semþ SeiIþ SedD
Sr ¼ Srmþ SriIþ SrdD
8><
>:
(1)
where Te and Tr are the mean durations of effort and rest epochs (fitted across experimental condi-
tions); I and D are the z-scored incentive and difficulty levels; Ai, Ad, Sei, Sed, Sri and Srd capture
potential modulations by task factors. The goal of model selection was to identify whether allowing
fewer modulations, e.g. only Ai, Sed and Sri, could still provide a reasonable goodness-of-fit. In total,
there are 26=64 possible combinations of the six modulations by task factors. However, we noted in
(Meyniel et al., 2013) that only 20 combinations can a priori reproduce the behavioral effects
observed in the effort allocation task (and potentially other effects): increased Te with incentive,
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decreased Tr with incentive, and decreased Te with difficulty. These 20 models correspond to four
possible combinations of the incentive effect: Ai;Sei;Srif g or Ai;Seif g or Ai;Srif g or Sei;Srif g crossed
with five possible combinations of the difficulty effect: Ad;Sed;Srdf g or Ad;Sedf g or Ad;Srdf g or
Sed;Srdf g or Sedf g. Besides these modulation terms, all models also included the mean accumulation
and dissipation slopes, Srm and Sem, as free parameters. Since effort and rest durations are deter-
mined by the ratios of amplitude and slopes in Equation 1, the mean amplitude Am was not consid-
ered as a free parameter; it was fixed to one, so that each subject could be characterized by a
unique set of best-fitting parameter values instead of an infinity of proportional solutions.
We used Bayesian model selection to identify a solution with the best tradeoff between good-
ness-of-fit and simplicity (number of modulation terms in the model). The 20 models were fitted for
each subject and visit separately using a variational Bayesian procedure described in
(Daunizeau et al., 2014). We used non-informative priors for the fitted parameter values. This varia-
tional procedure provides, for each visit and model, the posterior mean values of the latent parame-
ters and the model evidence. The latter is a key summary statistic on the basis of which the best
model is identified (Stephan et al., 2009; Daunizeau et al., 2014). In order to obtain a single sum-
mary statistic per subject, we took the joint (i.e., product of) model evidence over visits. The algo-
rithm used for group-level, random-effect Bayesian Model Selection is described in (Stephan et al.,
2009) and implemented in the Matlab toolbox SPM8 (Wellcome Department of Imaging Neurosci-
ence, London, UK; function spm_BMS.m).
Best computational model identified
In both treatment groups, Bayesian model selection (see Figure 2A) identified the following model
as providing the best trade-off between simplicity and goodness-of-fit of the data:
Te¼ A
Se
;Tr¼ A
Sr
;
A ¼ AmþAiI
Se ¼ Semþ SedD
Sr ¼ Srmþ SriI
8><
>:
(2)
This is the same best model as in our previous publication (Meyniel et al., 2013), although it is fit-
ted on different subjects. Fitted parameter values were on average positive such that higher incen-
tives expanded the bounds of cost-evidence variations and quickened its dissipation during rest and
higher difficulty levels increased the accumulation rate of cost-evidence during effort (see
Figure 2B).
This computational model can be interpreted as follows, for a more complete discussion see
(Meyniel et al., 2013, 2014). The accumulation of cost evidence may reflect the build-up of physio-
logical fatigue: the instantaneous effort cost increases as it becomes gradually more difficult to sus-
tain a given force level. As expected from a physiological perspective, fatigue builds up more
quickly when higher force levels are exerted, which is captured by Sed. An upper bound on the accu-
mulation process ensures that instantaneous cost remains within a certain range that is adjusted to
the reward rate. Indeed, the bound is pushed back for higher incentives (which is captured by Ai), as
if an extra cost is allowed when a higher benefit makes it worthy. The bounded accumulation mecha-
nism therefore seems to control the balance between cost and benefit, which could be implemented
as an opponency between brain systems (Daw et al., 2002; Balasubramani et al., 2015).
The dissipation of cost evidence may reflect that it takes time to recover full exercising capacity
after a strenuous effort. Interestingly, effort was not resumed immediately after cessation, but only
after a substantial decrease in cost evidence. Waiting until a lower bound is reached may ensure that
effort is not systematically produced at maximal instantaneous cost. Rest may therefore contribute
to optimizing the cost/benefit balance on the long run. Importantly, an exceedingly long rest would
also be suboptimal since it would reduce the payoff. Indeed, only efforts are rewarded in the task:
there is therefore an opportunity cost to rest (Niv et al., 2007). This opportunity cost seems to be
taken into account since the cost-evidence dissipation is speeded up for higher incentives (which is
captured by Sei), so that effort can be resumed more quickly.
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Specificity and sensitivity of the fitting procedure
The fitted parameter values were then compared between treatment groups (see below). We used
simulations to assess whether our fitting procedure can detect specific changes in the model param-
eters between groups. For each subject in the placebo group, we fitted the model and took the
mean value over visits of a given parameter (henceforth the ’target’). To simulate a potential effect
of the SSRI treatment on this target parameter, we increased this value by a 20%. Then we com-
puted mean effort and rest durations in each experimental condition using Equation 2 and we cor-
rupted these means with noise (we added the residuals of fitted data taken from another random
subject in the placebo group). Last, we fitted again the model by adjusting a second set of parame-
ters onto these simulated mean effort and rest durations. To assess statistical significance, we
repeated this procedure 100 times for each subject and each target parameter. We compared the
initial parameter values (fitted on actual data) and the new ones (fitted on simulated data) for each
simulation with paired t-test across subjects and the threshold p<0.05/5 to correct for the 5 parame-
ters tested. For ’target’ parameters, a significant difference indicates that the fitting procedure cor-
rectly recovers the simulated increase (a ’hit’); for ’non-target’ parameters, a significant difference
indicates a lack of specificity (a ’false alarm’). We report the simulated changes identified by the fit-
ting procedure in Figure 2C, as the median parameter change (across subjects), averaged over
simulations.
Specificity of the treatment effect
We also used Bayesian model comparison to test the specificity of treatment effect on computa-
tional parameters. We performed this comparison at the group level since our design is between-
subject and different subjects may have different parameter values irrespective of the treatment
type. To this end, we concatenated across subjects the mean effort and rest durations per condition,
separately for each group. The parameters of the accumulation model (Equation 2) were fitted onto
the placebo group data. These fitted values served as reference: Ai
REF, Sem
REF, Sed
REF, Srm
REF, Sri
REF.
We then modeled the potential treatment effect in the escitalopram group as a modulation of the
reference parameters: Ai = Ai
REF*(1+dAi), Sem= Sem
REF*(1+dSem), and so on for Sed, Srm or Sri. For
each parameter, the sign and value of d captures the direction and strength of the treatment effect
with respect to the placebo group. We designed single-modulation variants of the accumulation
model (Equation 2) by forcing d to zero for all but one parameter, for which d remained free. In
other words, a modulation of only one single parameter was permitted. We also designed double-
modulation models in which two modulations are permitted and modeled with distinct ds. All mod-
els were fitted with the variational Bayesian procedure by (Daunizeau et al., 2014). Values of log
model evidence are reported in Table 3 for model comparison.
Statistical analysis
We characterized the effect of treatments on (1) the monetary payoff, (2) the fitted parameters of
the best computational model (Equation 2), (3) the regression coefficients of the model-free analy-
sis. We provide source data files for each of these three sets of variables. We used a repeated-mea-
sure ANOVA with subjects as a random factor, treatment group as a between-subject factor and
time since treatment onset (initial, intermediate, late) as a within-subject factor. Interaction between
the within-subject factors was included in all ANOVAs. We followed up the ANOVA results with two-
sample two-sided t-tests at a given time since treatment onset. Significance levels corrected for
comparing multiple variables are included in Table 2.
Given our large sample size (N=58 included subjects), these classical parametric statistics reliably
quantify the likelihood that the observed differences between treatment groups reported in our
study may be due to chance in sampling the population. Indeed, we confirmed these significance
levels with non-parametric permutation tests, using 10,000 permutations of treatment labels
between subjects to estimate the probability that an equal or more extreme statistic (F or T depend-
ing on the test) could occur by chance.
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